News from ptc therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 02, 2012, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Announces Executive Promotions

 PTC Therapeutics, Inc. (PTC) today announced the promotions of Claudia Hirawat to President and Mark Boulding to Executive Vice President and...

Dec 22, 2011, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust

 PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5 million Seeding Drug Discovery (SDD) Award from the Wellcome Trust to...

Nov 29, 2011, 08:00 ET

Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)

 Roche (SIX: RO, ROG; OTCQX: RHHBY), PTC Therapeutics, Inc. (PTC) and the SMA Foundation, announced today a licensing agreement for PTC's...

Nov 07, 2011, 12:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Receives Grand Challenges Explorations Funding

PTC Therapeutics, Inc. announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill &...

Sep 02, 2011, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics and Genzyme Announce Restructuring of Collaboration

 PTC Therapeutics, Inc. and Genzyme, a Sanofi company, announced today the restructuring of their collaboration. Under the original...

Jul 01, 2011, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal

PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with...

Mar 30, 2011, 08:00 ET

PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer

PTC Therapeutics, Inc. (PTC) today announced the appointment of Robert J. Spiegel M.D., FACP as Chief Medical Officer.  Dr. Spiegel served...

Mar 02, 2011, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Announces Achievement of Milestone in BMI1 Collaboration With the Wellcome Trust

PTC Therapeutics, Inc. (PTC) today announced that it has identified a chemical series of molecules that penetrates the blood-brain barrier in...

Feb 01, 2011, 13:00 ET

PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients

PTC Therapeutics, Inc. (PTC) and Parent Project Muscular Dystrophy (PPMD) today announced an expansion of their collaboration to discover new...

Jan 19, 2011, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics' President and CEO Elected AAAS Fellow

Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the...

Dec 21, 2010, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis

PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in...

Dec 01, 2010, 08:00 ET

Observational Data From One-Year Follow-up Study Validate Six-Minute Walk Distance as an Outcome Measure in Duchenne and Becker Muscular Dystrophy

Data published in the December issue of the medical journal Muscle and Nerve confirm the utility of six-minute walk distance (6MWD) as a...

Nov 15, 2010, 08:00 ET

PTC Publishes Results from Phase 2 Study of Ataluren in Children with Cystic Fibrosis

PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic...

Oct 26, 2010, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren in Patients With Methylmalonic Acidemia

PTC Therapeutics, Inc. today announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a...

Oct 15, 2010, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

Pivotal Data Presented at the World Muscle Society Congress Suggest Ataluren Slows the Loss of Walking Ability in Patients with Nonsense Mutation Duchenne/Becker Muscular Dystrophy

PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss...

Sep 21, 2010, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis

PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office...

Jun 07, 2010, 08:00 ET

PTC Therapeutics Awarded $5.4 Million Grant From The Wellcome Trust

PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5.4 million Seeding Drug Discovery (SDD) Award from The Wellcome Trust to support...

Jan 19, 2010, 08:00 ET
A F PTC THERAPEUTICS, INC. PTC THERAPEUTICS, INC.

PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)[MF]
 SOUTH PLAINFIELD, N.J. UNITED STATES
 03/31/2006

PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy

PTC Therapeutics, Inc. (PTC) today announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with...

Dec 22, 2009, 08:00 ET
A F PTC THERAPEUTICS, INC. PTC THERAPEUTICS, INC.

PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)[MF]
 SOUTH PLAINFIELD, N.J. UNITED STATES
 03/31/2006

PTC Therapeutics Closes $50 Million Financing

PTC Therapeutics, Inc. (PTC) today announced the completion of a $50 million financing. The round was led by The Column Group - a new investor...

Dec 08, 2009, 08:00 ET
A F PTC THERAPEUTICS, INC. PTC THERAPEUTICS, INC.

PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)[MF]
 SOUTH PLAINFIELD, N.J. UNITED STATES
 03/31/2006

Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy

Data published online in the medical journal Muscle and Nerve support the use of the six-minute walk test (6MWT) as an outcome measure in PTC...